Global Hypertrophic Cardiomyopathy Therapeutics Market to Expand at a Restricted Pace of 1.40% by 2023 Limited by Technological Upgradation Transparency Market Research, in its latest report, states that the global hypertrophic cardiomyopathy therapeutics market is anticipated to witness tepid growth over the next seven years. Thoroughly analyzing the performance of the market from 2015 to 2023, the report - titled “Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023” – reveals that the global hypertrophic cardiomyopathy therapeutics market is forecast to rise from a value of US$1.2 bn in 2014 to US$1.4 bn in 2023, registering a 1.40% CAGR during that time.
Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010 stated that there was no significant gender and age range differences in the prevalence of HCM. Prevalence of HCM is higher among African-Americans compared to other races.